Role of vascular endothelial growth factor in maintenance of pregnancy in mice

Endocrinology

Volumn 154, Issue 2, 2013, Pages 900-910

  Wada, Yoshiko ^a   Ozaki, Hiromi ^a   Abe, Naomichi ^a   Mori, Asami ^a   Sakamoto, Kenji ^a   Nagamitsu, Tohru ^a   Nakahara, Tsutomu ^a   Ishii, Kunio ^a  

^a KITASATO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

KRN 633; N [2 CHLORO 4 [(6,7 DIMETHOXY 4 GUINAZOLINYL)OXY]PHENYL] N' PROPYLUREA; PROGESTERONE; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN INHIBITOR; VASCULOTROPIN RECEPTOR 2;

ANIMAL EXPERIMENT; ARTICLE; BIRTH; CONTROLLED STUDY; CORPUS LUTEUM; FEMALE; MOUSE; NONHUMAN; PREGNANCY; PREMATURE LABOR; PRIORITY JOURNAL; PROGESTERONE BLOOD LEVEL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; UTERUS CONTRACTILITY;

ANIMALS; CORPUS LUTEUM; FEMALE; MICE; MICE, INBRED ICR; PARTURITION; PHENYLUREA COMPOUNDS; PREGNANCY; PROGESTERONE; QUINAZOLINES; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84872696916     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/en.2012-1967     Document Type: Article

References (43)

1. Bastek JA, Sammel MD, Paré E, Srinivas SK, Posencheg MA, Elovitz MA. Adverse neonatal outcomes: examining the risks between preterm, late preterm, and term infants. Am J Obstet Gynecol. 2008;199:367.e1-e8.
2. McIntire DD, Leveno KJ. Neonatal mortality and morbidity rates in late preterm births compared with births at term. Obstet Gynecol. 2008;111:35-41.
3. American College of Obstetricians and Gynecologists. ACOG Committee Opinion. Use of progesterone to reduce preterm birth. Obstet Gynecol. 2003;102:1115-1116.
4. Risau W. Mechanisms of angiogenesis. Nature. 1997;386:671-674. (Pubitemid 27193480)
5. Shibuya M. Vascular endothelial growth factor (VEGF)-receptor2: its biological functions, major signaling pathway, and specific ligand VEGF-E. Endothelium. 2006;13:63-69. (Pubitemid 44173108)
6. Ferrara N, Chen H, Davis-Smyth T, et al. Vascular endothelial growth factor is essential for corpus luteum angiogenesis. Nat Med. 1998;4:336-340. (Pubitemid 28144094)
7. Wulff C, Wilson H, Rudge JS, Wiegand SJ, Lunn SF, Fraser HM. Luteal angiogenesis: prevention and intervention by treatment with vascular endothelial growth factor trap(A40). J Clin Endocrinol Metab. 2001;86:3377-3386. (Pubitemid 32673511)
8. Redmer DA, Reynolds LP. Angiogenesis in the ovary. Rev Reprod. 1996;1:182-192. (Pubitemid 27099364)
9. Kashida S, Sugino N, Takiguchi S, et al. Regulation and role of vascular endothelial growth factor in the corpus luteum during mid-pregnancy in rats. Biol Reprod. 2001;64:317-323. (Pubitemid 32044641)
10. Pauli SA, Tang H, Wang J, et al. The vascular endothelial growth factor (VEGF)/VEGF receptor 2 pathway is critical for blood vessel survival in corpora lutea of pregnancy in the rodent. Endocrinology. 2005;146:1301-1311. (Pubitemid 40289317)
11. Li Q, Wang H, Lin H, et al. Expression of vascular endothelial growth factor in rat ovary during pregnancy and postpartum. Sci China C Life Sci. 2002;45:379-387.
12. Mitchell BF, Taggart MJ. Are animal models relevant to key aspects of human parturition? Am J Physiol Regul Integr Comp Physiol. 2009;297:R525-R545.
13. Ratajczak CK, Fay JC, Muglia LJ. Preventing preterm birth: the past limitations and new potential of animal models. Dis Model Mech. 2010;3:407-414.
14. Nakamura K, Yamamoto A, Kamishohara M, et al. KRN633: a selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase that suppresses tumor angiogenesis and growth. Mol Cancer Ther. 2004;3:1639-1649. (Pubitemid 40136720)
15. Wada Y, Ozaki H, Abe N, et al. Effects of KRN633, an inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase, on vascular development of placenta and fetus of mid-pregnancy in mice. J Pharmacol Sci. 2010;112:290-298.
16. Thurston G, Baluk P, Hirata A, McDonald DM. Permeability-related changes revealed at endothelial cell borders in inflamed venules by lectin binding. Am J Physiol. 1996;271:H2547-H2562.
17. Christofori G, Naik P, Hanahan D. Vascular endothelial growth factor and its receptors, flt-1 and flk-1, are expressed in normal pancreatic islets and throughout islet cell tumorigenesis. Mol Endocrinol. 1995;9:1760-1770.
18. Eremina V, Jefferson JA, Kowalewska J, et al. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med. 2008;358:1129-1136. (Pubitemid 351398487)
19. Baffert F, Le T, Sennino B, et al. Cellular changes in normal blood capillaries undergoing regression after inhibition of VEGF signaling. Am J Physiol Heart Circ Physiol. 2006;290:H547-H559.
20. Eremina V, Jefferson JA, Kowalewska J, et al. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med. 2008;358:1129-1136. (Pubitemid 351398487)
21. Garfield, RE, Gasc JM, Baulieu EE. Effects of the antiprogesterone RU 486 on preterm birth in the rat. Am J Obstet Gynecol. 1987;157:1281-1285. (Pubitemid 17163822)
22. Dudley DJ, Branch DW, Edwin SS, Mitchell MD. Induction of preterm birth in mice by RU486. Biol Reprod. 1996;55:992-995. (Pubitemid 26346531)
23. Rowe AJ, Morris KD, Bicknell R, Fraser HM. Angiogenesis in the corpus luteum of early pregnancy in the marmoset and the effects of vascular endothelial growth factor immunoneutralization on establishment of pregnancy. Biol Reprod. 2002;67:1180-1188.
24. Kamba T, Tam BY, Hashizume H, et al. VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature. Am J Physiol Heart Circ Physiol. 2006;290:H560-H576.
25. Inai T, Mancuso M, Hashizume H, et al. Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. Am J Pathol. 2004;165:35-52. (Pubitemid 38821812)
26. He H, Venema VJ, Gu X, Venema RC, Marrero MB, Caldwell RB. Vascular endothelial growth factor signals endothelial cell production of nitric oxide and prostacyclin through flk-1/KDR activation of c-Src. J Biol Chem. 1999;274:25130-25135.
27. Peppiatt CM, Howarth C, Mobbs P, Attwell D. Bidirectional control of CNS capillary diameter by pericytes. Nature. 2006;443:700-704. (Pubitemid 44564713)
28. Kutcher ME, Herman IM. The pericyte: cellular regulator of microvascular blood flow. Microvasc Res. 2009;77:235-246.
29. Hellström M, Gerhardt H, Kalén M, et al. Lack of pericytes leads to endothelial hyperplasia and abnormal vascular morphogenesis. J Cell Biol. 2001;153:543-553. (Pubitemid 34280141)
30. Morishige WK, Pepe GJ, Rothchild I. Serum luteinizing hormone, prolactin and progesterone levels during pregnancy in the rat. Endocrinology. 1973;92:1527-1530.
31. McCormack JT, Greenwald GS. Progesterone and oestradiol-17beta concentrations in the peripheral plasma during pregnancy in the mouse. J Endocrinol. 1974;62:101-107.
32. Fraser HM, Wilson H, Wulff C, Rudge JS, Wiegand SJ. Administration of vascular endothelial growth factor Trap during the "post-angiogenic" period of the luteal phase causes rapid functional luteolysis and selective endothelial cell death in the marmoset. Reproduction. 2006;132:589-600. (Pubitemid 44660533)
33. Sugimoto Y, Yamasaki A, Segi E, et al. Failure of parturition in mice lacking the prostaglandin F receptor. Science. 1997;277:681-683. (Pubitemid 27373912)
34. Tropea A, Miceli F, Minici F, et al. Regulation of vascular endothelial growth factor synthesis and release by human luteal cells in vitro. J Clin Endocrinol Metab. 2006;91:2303-2309. (Pubitemid 43855021)
35. Berisha B, Meyer HH, Schams D. Effect of prostaglandin F2 alpha on local luteotropic and angiogenic factors during induced functional luteolysis in the bovine corpus luteum. Biol Reprod. 2010;82:940-947.
36. Al-zi'abi MO, Watson ED, Fraser HM. Angiogenesis and vascular endothelial growth factor expression in the equine corpus luteum. Reproduction. 2003;125:259-270.
37. Neuvians TP, Berisha B, Schams D. Vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF) expression during induced luteolysis in the bovine corpus luteum. Mol Reprod Dev. 2004;67:389-395. (Pubitemid 38298712)
38. Kurusu S, Kaizo K, Ibashi M, Kawaminami M, Hashimoto I. Luteal phospholipase A2 activity increases during functional and structural luteolysis in pregnant rats. FEBS Lett. 1999;454:225-228. (Pubitemid 29304605)
39. Meis PJ, Klebanoff M, Thom E, et al.; National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate. N Engl J Med. 2003;348:2379-2385. (Pubitemid 36682816)
40. Gupta S, Roman AS. 17-α hydroxyprogesterone caproate for the prevention of preterm birth. Womens Health (Lond Engl). 2012;8:21-30.
41. Boroditsky RS, Reyes FI, Winter JS, Faiman C. Maternal serum estrogen and progesterone concentrations preceding normal labor. Obstet Gynecol. 1978;51:686-691. (Pubitemid 8337982)
42. Mathur RS, Landgrebe S, Williamson HO. Progesterone, 17- hydroxyprogesterone, estradiol, and estriol in late pregnancy and labor. Am J Obstet Gynecol. 1980;136:25-27. (Pubitemid 10160057)
43. Smith R, Smith JI, Shen X, et al. Patterns of plasma corticotropin- releasing hormone, progesterone, estradiol, and estriol change and the onset of human labor. J Clin Endocrinol Metab. 2009;94:2066-2074.